-- 独立研究机构CFRA向提供了以下研究报告。CFRA的分析师总结如下：杜比视界(DLB)第二季度业绩略微超出预期，营收为3.956亿美元（同比增长7.1%），比市场普遍预期高出1020万美元；非GAAP每股收益为1.37美元，比市场预期高出0.03美元，主要得益于授权收入增长7.6%至3.722亿美元。广播业务的强劲表现（同比增长26.5%至1.192亿美元）表明，杜比视界2.0计划正逐渐获得电视OEM厂商的青睐，标志着该业务从去年同期的下滑（-11%）中显著复苏。然而，移动业务在经历了强劲的第一季度后有所放缓（同比下降5.9%至9420万美元），不过最低销量承诺在一定程度上缓解了这一影响。管理层对第三季度的展望较为保守，预计营收为2.95亿美元至3.25亿美元，每股收益为0.56美元至0.71美元，均低于市场预期。DLB维持其2026财年营收14亿美元至14.5亿美元、每股收益4.30美元至4.45美元的预期。我们认为，各业务板块表现不一反映了整体市场压力，尽管面临关税和存储器价格上涨的不利因素，消费电子（+7.4%）和其他业务板块（+6.0%）仍展现出韧性。88.7%的强劲利润率和6500万美元的股票回购表明公司拥有健康的现金流和资本配置能力。
Related Articles
Research
Research Alert: CFRA Reiterates Sell Opinion On Shares Of Hilton Worldwide Holdings Inc
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month price target by $9 to $293, or 32x our 2026 EPS estimate (unchanged) and in line with shares' five-year average forward multiple. We raise our 2026 EPS estimate to $9.16 from $8.88 and lower 2027's to $10.03 from $10.20. Following Q1 results that beat expectations and included raised guidance, we maintain our 2-STARS (Sell) rating. U.S. RevPAR performance broadened from primarily luxury and upper upscale segments to include more meaningful midscale contribution, which management attributes to the return of middle- and low-income consumers. However, we note Q1 results also included ADR deceleration, particularly among luxury hotels, which historically drive significant profit contribution. HLT's Q2 EBITDA guidance of $1,015-$1,035 million being below the $1,081 million consensus suggests luxury pricing power is weakening faster than midscale volume can offset. While the broadening demand trend is positive, we believe slowing luxury tailwinds limit upside at current valuation levels.
$HLT
Research
Research Alert: CFRA Maintains Buy Rating On Shares Of Universal Health Services
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $200 from $243, reflecting an 8.7x multiple of our 2026 EPS estimate, below peer multiples and a discount to UHS's five-year historical forward average of 11.9x. We lower our 2026 EPS forecast to $22.95 from $23.39 and cut our 2027 view to $25.48 from $25.67. Q1 inpatient volumes were flat on a same-facility basis, with seasonal headwinds from unfavorable winter weather and a milder flu/respiratory illness period. The recent expiration of ACA EPTCs also posed challenges, as UHS estimates a near 5% drop in ACA adjusted admissions relative to Q1 2025. UHS maintained its prior forecast of a 25%-30% decline in ACA exchange volumes during the full year, which represented around 6% of the acute care business adjusted admissions in 2025 and under 5% of the acute care segment revenues. UHS anticipates a $75M pre-tax earnings hit in 2026 from these developments, unchanged from prior guidance.
$UHS
Asia
Shenghe Resources' Q1 Profit Jumps 94%, Revenue Climbs 13%
Shenghe Resources' (SHA:600392) net profit attributable to shareholders in the first quarter jumped 94% to 327.3 million yuan from 168.3 million yuan a year earlier, according to a Shanghai bourse filing on Thursday.Earnings per share rose year on year to 0.1867 yuan from 0.0960 yuan.The Chinese rare earth miner's operating revenue climbed 13% to 3.38 billion yuan from 2.99 billion yuan in the previous year.
$SHA:600392